AVBP · Insider Trading
ArriVent BioPharma, Inc. Common Stock
Every open-market purchase and sale reported by AVBP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | John Hohneker | Director | A | +13,562 deriv. | — |
| 2026-06-22 | Merdad Parsey | Director | A | +13,562 deriv. | — |
| 2026-06-22 | Kristine Peterson | Director | A | +13,562 deriv. | — |
| 2026-06-22 | Chris Nolet | Director | A | +13,562 deriv. | — |
| 2026-02-04 | James Paul Kastenmayer | General Counsel | A | +130,000 deriv. | — |
| 2026-02-04 | Stuart Lutzker | President of R&D | A | +150,000 deriv. | — |
| 2026-02-04 | Zhengbin Yao | President and CEO | A | +550,000 deriv. | — |
| 2026-02-04 | Robin LaChapelle | Chief Operating Officer | A | +130,000 deriv. | — |
| 2026-02-04 | Winston Kung | Chief Financial Officer | A | +140,000 deriv. | — |
| 2026-02-03 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10%+ Owner | Sell | −1,111,110 | −$25.97M |
| 2025-07-15 | Robin LaChapelle | Chief Operating Officer | M | +11,153 | +$25.43K |
| 2025-06-20 | Chris Nolet | Director | A | +15,502 deriv. | — |
| 2025-06-20 | Kristine Peterson | Director | A | +15,502 deriv. | — |
| 2025-06-20 | John Hohneker | Director | A | +15,502 deriv. | — |
| 2025-06-20 | Merdad Parsey | Director | A | +15,502 deriv. | — |
| 2025-04-29 | Merdad Parsey | Director | A | +28,346 deriv. | — |
| 2025-02-14 | James Paul Kastenmayer | General Counsel | A | +102,000 deriv. | — |
| 2025-02-14 | Stuart Lutzker | President of R&D | A | +120,000 deriv. | — |
| 2025-02-14 | Winston Kung | Chief Financial Officer | A | +120,000 deriv. | — |
| 2025-02-14 | Robin LaChapelle | Chief Operating Officer | A | +120,000 deriv. | — |
| 2025-02-14 | Zhengbin Yao | President and CEO | A | +380,000 deriv. | — |
| 2024-09-23 | Robin LaChapelle | Chief Operating Officer | M | +27,566 | +$90.48K |
| 2024-05-20 | John Hohneker | Director | A | +29,550 deriv. | — |
| 2024-04-23 | Kristine Peterson | Director | A | +28,587 deriv. | — |
| 2024-02-01 | HHLR ADVISORS, LTD. | 10%+ Owner | MIXED | +8,969,344 | +$20.00M |
| 2024-01-31 | Carl L Gordon | Director | MIXED | +3,027,328 | +$8.00M |
| 2024-01-31 | OrbiMed Advisors IV Ltd | Director | MIXED | +12,109,312 | +$32.00M |
| 2024-01-31 | James Healy | Director | MIXED | +1,696,752 | +$8.00M |
| 2024-01-29 | Chris Nolet | Director | A | +17,884 deriv. | — |
| 2024-01-29 | Bahija Jallal | Director | A | +17,884 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMENT, LTD. | 10%+ Owner | 3,929,117 | $60.35M |
| Robin LaChapelle | Chief Operating Officer | 521,110 | $8.00M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVBP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.